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A new age in functional genomics
using CRISPR/Cas9 in arrayed library
screening
Alexander Agrotis and Robin Ketteler*
MRC Laboratory for Molecular Cell Biology, University College London, London, UK
CRISPR technology has rapidly changed the face of biological research, such that
precise genome editing has now become routine for many labs within several years
of its initial development. What makes CRISPR/Cas9 so revolutionary is the ability to
target a protein (Cas9) to an exact genomic locus, through designing a specific short
complementary nucleotide sequence, that together with a common scaffold sequence,
constitute the guide RNA bridging the protein and the DNA. Wild-type Cas9 cleaves both
DNA strands at its target sequence, but this protein can also be modified to exert many
other functions. For instance, by attaching an activation domain to catalytically inactive
Cas9 and targeting a promoter region, it is possible to stimulate the expression of a
specific endogenous gene. In principle, any genomic region can be targeted, and recent
efforts have successfully generated pooled guide RNA libraries for coding and regulatory
regions of human, mouse and Drosophila genomes with high coverage, thus facilitating
functional phenotypic screening. In this review, we will highlight recent developments in
the area of CRISPR-based functional genomics and discuss potential future directions,
with a special focus on mammalian cell systems and arrayed library screening.
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Introduction
Functional genomics is a powerful technique to identify gene function, in particular through
assessing cellular phenotypes arising from genome-wide perturbations. A classical approach to
achieve such perturbations has been to alter the copy number of a gene, mRNA or protein.
Historically, two opposing yet complementary methods have been established for this purpose:
gain-of-function, including cDNA expression cloning; and loss-of-function, including short
interfering (si) RNA knockdown experiments (Yao et al., 2015). These have been particularly
useful for high-throughput screening approaches. Both cDNA and siRNA libraries are available
from several commercial vendors in arrayed format, thus providing a convenient way of studying
gene function on a genome-wide scale. However, conventional screening methods have lacked a
certain degree of control over expression levels. For instance, cDNA libraries are often expressed
at a high level that may raise questions over the physiological relevance of observed phenotypes.
Nonetheless, expression cloning has proved a very useful tool, enabling discoveries which can be
validated, for instance in the identiﬁcation of virus receptors and cell surface receptor signaling
eﬀectors (Seed, 1995). The main method for genome-wide loss-of-function screening is using
short hairpin (sh) RNA or siRNA libraries in order to reduce mRNA transcript levels. This has
been successfully utilized to study aspects of mitosis (Neumann et al., 2006), virus un-coating
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(Kilcher et al., 2014), autophagy (McKnight et al., 2012), and
cancer signaling (Schlabach et al., 2008), to name just a few
examples. However, the levels of mRNA knockdown achieved
are variable and frequently incomplete and oﬀ-target eﬀects can
occur that lead to non-speciﬁc knockdown (Buehler et al., 2012).
More recently developed techniques utilizing genome editing and
functionalization technologies have pushed the boundaries of
gain- or loss-of-function experiments. It is now possible to make
much more precise changes to endogenous gene expression level
and protein function.
Genome editing involves making permanent changes to a
genome DNA sequence using targeted nucleases, whilst genome
functionalization refers to any type of targeted perturbation to
the genome (e.g., gene activation, chromatin remodeling) that
does not cause a permanent change in the DNA sequence. In
the past, both approaches have been successfully performed using
engineered zinc ﬁnger nucleases and transcription activator-
like eﬀector-based nucleases (TALENs) to study individual gene
function, and also meganucleases have been used exclusively for
genome editing (Joung and Sander, 2013). However, it has been
pointed out that due to the challenges in construct engineering
for these systems, which rely on protein–DNA interactions for
targeting, it is diﬃcult to exploit their potential in large-scale
screening approaches in which many diﬀerent genes must be
individually targeted (Reyon et al., 2012; Heintze et al., 2013).
The recent development of clustered regularly interspaced
short palindromic repeat (CRISPR)/Cas9 for experimental
purposes has dismantled the perception that genome editing
technology is oﬀ-limits for screening in mammalian systems
(Heintze et al., 2013). Since this system employs the basic
principle of Watson-Crick base pairing for gene targeting,
generation of libraries with whole-genome target coverage is
relatively easy and cost-eﬀective. For instance, simple protocols
are available to synthesize pooled lentiviral libraries by in
silico design of oligonucleotides, which can then be cloned,
packaged and delivered to cells by viral transduction (Paddison
et al., 2004; LeProust et al., 2010). Similarly, the generation of
arrayed libraries can be achieved by following protocols originally
developed for arrayed shRNA library production that have been
in use for a number of years (Moﬀat et al., 2006). All in all, the
stage is set for CRISPR to make an enormous impact on genomic
screening and thus scientiﬁc discovery in the coming years, and
recent demonstrations of this system have shown great promise
(Shalem et al., 2015). However, a number of technical challenges
must be addressed in order to maximize the beneﬁt of this
technology. In this review, we will discuss current applications
of CRISPR in functional genomics and provide a perspective on
future developments in this area.
CRISPR/Cas9 Genome Editing
CRISPRwas identiﬁed as part of an adaptive immunemechanism
in bacteria to destroy foreign DNA from sources such as
bacteriophages and plasmids (Barrangou et al., 2007). Type II
CRISPR systems integrate short sequence stretches of foreign
DNA between CRISPR elements in the bacterial host genome.
Transcripts from these repeats are processed into CRISPR RNAs
(crRNA) containing the stretch of sequence (spacer sequence)
resembling a part of the target foreign DNA (protospacer
sequence). The crRNA can associate via base-pairing with
another RNA that acts as a scaﬀold, the trans-activating CRISPR
RNA (tracrRNA), and this RNA complex can then associate
with the Crispr ASsociated (Cas) nuclease (Jinek et al., 2012).
In the target DNA, the protospacer sequence is adjacent to a
short (2–5 bp) sequence known as the protospacer adjacent
motif (PAM) – together these direct the crRNA/Cas complex
to the exact location in the foreign DNA, with the requirement
for the PAM additionally ensuring that the host CRISPR locus
(which lacks a PAM) is not targeted (Sternberg et al., 2014).
Cas9 catalyzes cleavage of both strands of DNA at the site
three nucleotides upstream of the PAM, resulting in degradation
of the foreign DNA. This system therefore provides a form
of host memory of the invading pathogen DNA, enabling
the same pathogenic sequence to be targeted recurrently. The
pairing of the RNA component with Cas9 also allows multiple
distinct sequences to be targeted individually by a common Cas9
protein.
The type II CRISPR system from Streptococcus pyogenes has
been adapted for targeted genome editing in eukaryotic cells
(Cong et al., 2013; Jinek et al., 2013; Mali et al., 2013a,b). In
a three-component system that is reminiscent of the natural
system, the two RNA components (crRNA and tracrRNA) are
introduced into cells or ectopically expressed along with a codon-
optimized Cas9. When the crRNA and tracrRNA are artiﬁcially
fused as a fully functional single “guide” (sg) RNA this becomes
an even simpler two-component system, consisting of just the
sgRNA and Cas9 (Jinek et al., 2013). The principle of targeting
in both systems remains the same. The host genome of interest is
targeted for disruption by identifying a suitable PAM motif and
designing a targeting sequence speciﬁc for the adjacent region,
to incorporate into the crRNA or sgRNA. This allows Cas9 to
be recruited to the desired locus to exert its function, most
commonly by forming double-strand breaks (DSB) in the DNA
in the case of “wild-type” Cas9 (Figure 1). The presence of a DSB
initiates host-mediated cellular repair pathways; in the absence
of a repair template, non-homologous end-joining (NHEJ) is
carried out. This error-prone mechanism frequently causes
insertions or deletions (indels) in the DNA that can result in
frame-shifting and disruption of the gene (Jinek et al., 2013). If a
repair template is available then homology-directed repair (HDR)
may occur. This principle is exploited for performing knock-
ins using CRISPR; by providing an artiﬁcial repair template
in addition to the two or three CRISPR components, one can
eﬃciently introduce recombinant DNA into the genome at a
deﬁned location.
In addition to the targeting of Cas9 to a speciﬁc DNA
sequence, the protein itself must be targeted to a speciﬁc cellular
compartment, for instance by the attachment of a nuclear
localization signal. Targeting other locations in the cell is possible
in principle, and has been done for alternative genome editing
methods such as TALENs, e.g., targeting to mitochondria by
insertion of a mitochondrial targeting signal (Bacman et al.,
2013).
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FIGURE 1 | The mechanism of genome editing using CRISPR/Cas9. The genomic DNA target, which must lie adjacent to a protospacer adjacent motif (PAM),
is specified by a 20 nt user-generated guide sequence in the sgRNA or crRNA. The Streptococcus pyogenes PAM is shown. In the cell nucleus, Cas9 protein
associates with the sgRNA or crRNA/tracrRNA and binds to the target sequence, cleaving both strands of the DNA at the site 3 nt upstream of the PAM. Cleavage
results in a DSB which is repaired by host-mediated DNA repair mechanisms. In the absence of a repair template, error-prone NHEJ occurs which may lead to the
formation of random short indels and thus frameshift mutations and disruption of gene function, and this represents the main method of CRISPR-mediated gene
knockout generation. If an artificial repair template is provided, for example on a plasmid containing a sequence of interest flanked by homology arms, then HDR may
occur, leading to the introduction of an exogenous DNA sequence at a specified genomic location. This is the basis for performing gene knock-in, tagging, and
precise pre-specified insertions or deletions using CRISPR. If catalytically inactive Cas9 is used instead of wild-type Cas9, then the protein simply binds to the target
locus and does not cleave the DNA.
Cas9 is presently the best-studied member of the Cas protein
nucleases, although there are other members, and homologs in
species other than S. pyogenes that have a similar role in bacterial
host defense (Makarova et al., 2011; van Der Oost et al., 2014).
Interestingly, type I and III Cas proteins require an additional
component, the Cas3 helicase, to unwind the target DNA. This
is not required for type II Cas proteins such as Cas9, explaining
why this has been the preferred choice for use in genome editing
technologies. As homologs of Cas9 vary in terms of the PAM
sequence they recognize, diﬀerent Cas9 proteins may be chosen
to expand the range of genomic loci available for targeting (Shah
et al., 2013), and recently S. pyogenes Cas9 was successfully
engineered using a mutagenesis screen to obtain diﬀerent PAM
speciﬁcities (Kleinstiver et al., 2015). These developments are
important because as the potential of CRISPR technology grows,
so does the requirement for more precise targeting along with
minimizing oﬀ-target eﬀects.
One caveat of current CRISPR technology is that the Cas9
protein is rather large (∼158 kDa in molecular mass), which has
certain disadvantages, such as limiting viral titer when attempting
to package the Cas9 coding sequence and consequently making
this diﬃcult to introduce into certain cell types. To help overcome
this problem, a slightly smaller Cas9 from Staphylococcus aureus
(approximately 124 kDa) has recently been described (Ran
et al., 2015). Structural and biochemical studies have helped to
reveal elements of the mechanism of Cas9 function and identify
the domains involved in DNA binding; these may contribute
to the design of smaller Cas9 proteins suitable for genome
editing and functionalization. It has been noted from the crystal
structure of Cas9 in complex with a guide RNA and target
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DNA (Nishimasu et al., 2014), and single-molecule based assays,
that Cas9 itself contributes signiﬁcantly to DNA binding (Jiang
and Doudna, 2015). In fact, in vitro data suggests that PAM
recognition by Cas9 precedes target site recognition by the
RNA component (Sternberg et al., 2014). In addition, speciﬁcally
targeted Cas9 remains strongly bound to its substrate DNA post-
cleavage (Sternberg et al., 2014) and this feature may contribute
signiﬁcantly to the usefulness of engineered Cas9 in cells and in
vivo.
From Genome Editing to Genome
Functionalization
The Cas9 protein has been engineered to obtain various
properties that range from transcriptional repression to
endogenous gene tagging (Table 1). In a more simpliﬁed view,
Cas9 can be seen as the adaptor between the target sequence and
a variety of functions. This reveals the most powerful concept of
CRISPR technology: the ability to target a function to an exact
genomic position. With this view in mind, it is conceivable to
be able to design a minimal Cas9 protein with all extraneous
regions deleted so that the protein simply binds the target DNA,
and this would provide the most basic possible template for
protein engineering. To date, successful CRISPR-based genome
functionalization techniques have been based on fusing one or
several functional domain to full-length catalytically inactive
Cas9 (dCas9), which binds to the target locus but does not
cleave the DNA. An important experimental consideration
to take into account when following these approaches is that
diﬀerent sgRNAs must be designed for each functionalization
in order to target the correct genomic features and achieve the
desired output. For instance, transcriptional regulation requires
sgRNAs that target promoter or regulatory regions, whereas
sgRNAs used for knockouts most commonly target exons.
Furthermore, the location of targeting within an individual gene
can have a signiﬁcant impact on the functional eﬀect of the
resulting mutation. For example, when using wild-type Cas9,
targeting a coding region corresponding to a functional protein
domain has been shown to be result in loss-of-function even for
in-frame mutations, compared to exclusively targeting early exon
regions, which often require frameshift mutations to achieve
loss-of-function (Shi et al., 2015). Deliberately targeting certain
gene regions can be used for achieving speciﬁc outcomes, such as
knocking out a speciﬁc splice variant.
Overall, the broad range of functional modalities coupled
with an elegant targeting mechanism makes CRISPR systems
very attractive compared to alternative functional genomics tools.
For instance, cDNA libraries are restricted to gain of function
applications and siRNA knockdown to mRNA silencing. Such
simpliﬁcations can easily overlook the advantages of classical
systems, however. For instance, siRNA applications do not
require the introduction of a exogenous nuclease, and the long-
term eﬀect of Cas9 expression in cells and tissues has not
been fully appreciated (Shalem et al., 2015). siRNAs are very
eﬀective in short time frames ranging from 1 to 3 days, making
this an attractive approach for microwell based screening, since
cultivation of cells within a microwell format for longer than
3 days poses challenges with overgrowth and subsequent high-
content analysis of phenotype (Table 2).
CRISPR/Cas9 Screening
A growing number of published studies have utilized CRISPR
technology for screening (see Table 3 for a comparison). CRISPR
TABLE 1 | Comparison of the different Cas9 functions that have been successfully demonstrated.
Function Cas9
variant
Effector domain sgRNA target Detection method Reference
Knockout and Knockin WT
nickase
–
–
ORF HRM; IDAA; Mismatch
endonuclease;
Cong et al., 2013; Jinek et al.,
2013; Mali et al., 2013a
dCas9 Fok I PAGE; Western blot;
Sanger Sequencing;
Guilinger et al., 2014; Tsai et al.,
2014
Activation dCas9 Multimers of VP16 (VP48,
VP64, VP160) p65 SunTag
Promoter RT-PCR
Western blot
Cheng et al., 2013; Gilbert et al.,
2013; Maeder et al., 2013; Mali
et al., 2013a; Tanenbaum et al.,
2014; Konermann et al., 2015
Silencing dCas9 KRAB Promoter RT-PCR
Western blot
Larson et al., 2013; Qi et al., 2013;
Gilbert et al., 2014
Gene tagging dCas9 GFP/SunTag Any Immunostaining
Microscopy Western blot
Tanenbaum et al., 2014
Genome locus visualization dCas9 BFP EGFP
GFP, 3xGFP, mCherry
Any Microscopy Chen et al., 2013; Ma et al., 2015
Optogenetic activation dCas9 CIB1/CRY2 Promoter Variable Nihongaki et al., 2015; Polstein and
Gersbach, 2015
Split reporter Split Cas9 – Any Variable Truong et al., 2015; Wright et al.,
2015
ORF, open reading frame; HRM, high-resolution melt analysis; IDAA, indel detection by amplicon analysis; PAGE, poly-acrylamide electrophoresis; VP16, tegument protein
VP16 of herpes simplex virus; SunTag, peptide array that recruites multiple copies of an antibody fusion protein and GFP; KRAB, Kruppel associated box; EGFP, enhanced
green fluorescent protein; BFP, blue fluorescent protein; CIB1, calcium and integrin binding 1; CRY2, cryptochrome circadian clock 2.
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TABLE 2 | Key characteristics in CRISPR and siRNA technologies.
siRNA CRISPR
Targeting sequence siRNA Oligonucleotide
shRNA plasmid
(Synthetic sgRNA)
sgRNA plasmid
Effector - (Endogenous) Cas9 Endonuclease
Effect Knockdown (variable) Knockout
(Silencing, Activation)
Time to effect 2–3 days Days; may require selection
Libraries Lentiviral shRNA Pools
Lentiviral shRNA arrays
Arrayed siRNA
Sub-panels
Lentiviral sgRNA Pools
Off-target effects High No consensus reached –
Depending on policy of lab
off-targets may be absent
or very high
For an overview of key differences between siRNA and CRISPR technologies,
please see Taylor and Woodcock (2015).
screening can be performed using pooled library approaches
coupled to positive or negative selection, or alternatively arrayed
libraries (Figure 2). To date, all studies have employed a pooled
library approach, and whilst performed primarily as a proof-
of-principle, these have uncovered novel genes that enhance or
suppress simple phenotypes such as toxicity-induced cell death
(Gilbert et al., 2014; Koike-Yusa et al., 2014; Shalem et al., 2014;
Wang et al., 2014; Zhou et al., 2014; Konermann et al., 2015).
They have also helped conﬁrm important parameters of eﬀective
sgRNA design, which will undoubtedly assist the production of
future libraries. A summary of these design considerations is
listed in a recommended technical resource (Malina et al., 2014).
The basis of pooled library screening using CRISPR is ﬁrstly
the production of a complex mixture of thousands of unique
sgRNA-containing vectors, before delivery of the entire library to
a single vessel of cells by viral transduction at low multiplicity
of infection (MOI). Low MOI is absolutely crucial to limit
the probability that an individual cell clone possesses more
than one sgRNA, which would interfere with the assignment of
genotype to phenotype in a mixed cell population. The sgRNAs
can be designed with the aid of bioinformatic computational
tools that assist in the identiﬁcation of appropriate target
sequences adjacent to PAMs, and libraries can be designed
either with whole-genome coverage or for speciﬁc gene sets
of interest, with single or multiple sgRNA designs per gene.
The PAM is a ﬁxed determinant in library design, restricting
the number of possible targeting sequences in the genome.
Nonetheless, it was estimated that every gene contains several
such potential target sites (Montague et al., 2014), although this
may diﬀer for other genomic elements such as promoters. To
date, no obvious targeting limitations imposed by chromatin
accessibility or structure have been observed. The range of
available sgRNA design tools is expanding and it can be beneﬁcial
to evaluate potential sgRNA sequences by taking advantage of
multiple programs (Doench et al., 2014; Heigwer et al., 2014;
Montague et al., 2014; Xie et al., 2014; Chari et al., 2015;
Hodgkins et al., 2015; Naito et al., 2015; Prykhozhij et al.,
2015).
In pooled screens, wild-type Cas9 or a modiﬁed derivative can
either be stably expressed in the target cell line or encoded on the
same viral vector as the sgRNA. After viral delivery of the library
and selection for transduced cells, further selections are carried
out for speciﬁc phenotypes of interest (for example by treatment
with a compound which confers selective pressure for resistance
phenotypes). The ﬁnal step in the screen, which provides the
read-out, is the deep sequencing of PCR-ampliﬁed genomic
DNA from selected clones compared to an unselected control
cell population, using sequencing primers targeting sgRNAs,
to reveal the sgRNAs that are enriched or depleted following
selection. Raw data of sequencing reads must be mapped against
the original sgRNA library, annotated with the target gene
that each sgRNA corresponds to, and statistical analysis is
necessary to identify genes which are signiﬁcantly likely to be
relevant to the phenotype of interest. It is noteworthy that
the sequencing step reveals the identity and relative abundance
of integrated sgRNAs in the cell population rather than the
occurrence of modiﬁcations (such as indels) at respective target
loci, however the demonstrated high eﬃciency of CRISPRmeans
that it is assumed that the majority of well-designed sgRNAs
are successful in recruiting Cas9 function. Nonetheless, due
to the incomplete knowledge of individual sgRNA eﬃciencies
across a large library, and their varying potential for oﬀ-target
eﬀects, hits are typically only considered if multiple distinct
sgRNAs targeting the same gene produce the same phenotype.
The identiﬁcation of known regulators provides assurance of a
robust screen, and most prior studies have included additional
internal controls to aid the evaluation of chosen experimental
design.
Shalem et al. (2014) and Wang et al. (2014) and were amongst
the ﬁrst to demonstrate the feasibility of genome-wide loss-
of-function-based screening using CRISPR and its advantages
over siRNA in human cell lines. Whilst Wang et al. generated
stable Cas9-expressing cell lines before transduction with sgRNA-
containing lentiviral particles, Shalem et al. (2014) designed
a “lentiCRISPR” vector containing adjacent sgRNA and Cas9
expression cassettes. Both systems made positive and negative
selection screens possible. Positive selection, in which enriched
sgRNAs are detected, has been adopted in all pooled studies
and proved to be highly successful with few drawbacks. Negative
selection, however, requires the screen to be carried out a large
scale to ensure that entire library is represented multiple times
over, providing suﬃcient sensitivity for depleted sgRNAs to
be deduced from the ﬁnal cell population. Zhou et al. (2014)
proposed the beneﬁts of smaller libraries focused on speciﬁc
gene sets – an approach which is more broadly accessible and
likely to be adopted for developing arrayed libraries. Bassett
et al. (2015) generated aDrosophilawhole genome sgRNA library
where both sgRNA and wild-type humanized Cas9 are expressed
from a single bicistronic expression plasmid. One caveat of this
transfection-based system is that each cell will obtain multiple
sgRNAs, resulting in lower signal levels. This can be overcome
by dilution of the library in inert carrier DNA and will need to be
tested in more detail.
Whilst the loss-of-function studies using wild-type Cas9
represent a milestone in demonstrating the utility of CRISPR
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TABLE 3 | Description of key published studies to date using pooled CRISPR-based screening libraries.
Study reference Cas9
system
Library size, genes
targeted
Cell type(s) Selection Key findings with implications for
screening
Wang et al., 2014 WT Cas9 stably
expressed.
73,151 sgRNAs
7,114 genes
10 sgRNA/gene
Human KBM7
(CML)
HL60 (PML)
6-thioguanine
Etoposide
Proliferation
CRISPR-based KO screening is effective in
both haploid and diploid cells.
Off-target effects are minimal.
Shalem et al., 2014 WT Cas9 encoded in
same lentivirus as sgRNA
64,751 sgRNAs
18,080 genes
3-4 sgRNA/gene
Human A375
(melanoma)
HUES62 (stem cell
line)
Proliferation
Vemurafenib
CRISPR-based KO screening produces
strong phenotypes that may be
undetectable using RNAi.
Hits have a high validation rate.
Koike-Yusa et al., 2014 WT Cas9 stably
expressed
87,897 sgRNAs
19,150 genes
2-5 sgRNA/gene
Mouse JM8 (ES cell
line)
Alpha toxin
6-thioguanine
CRISPR is powerful enough to be used for
recessive screens.
Off target effects are low, subject to
effective sgRNA design.
Lentiviral-delivered sgRNA guide
sequences are most effective if the first
nucleotide is a G.
Zhou et al., 2014 WT Cas9 stably
expressed, OCT4 stably
expressed to boost U6
promoter
869 sgRNA
291 genes
∼3 sgRNA/gene
Human HeLa
(adenocarcinoma)
Diptheria toxin
Chimaeric anthrax
CRISPR has advantages over RNAi for
knowledge-based screening with small
focused libraries.
It is important to select a clonal Cas9 cell
line with a high modification efficiency.
Bassett et al., 2015 WT Cas9 encoded in
same plasmid as sgRNA
40,279 sgRNA
13,501 genes
∼3 sgRNA/gene
Drosophila S2R+
cells
Proliferation First Drosophila whole genome sgRNA
library.
Plasmid transfection can be used in pooled
approaches if DNA is diluted and cells are
selected.
Gilbert et al., 2014 CRISPRi: dCas9-KRAB
stably expressed
CRISPRa:
sunCas9 stably
expressed
206,421 sgRNAs
15,977 genes
∼10 sgRNA/gene
198,810 sgRNAs
15,977 genes
∼10 sgRNA/gene
Human K562 (CML) Proliferation
Chimaeric cholera
toxin-diptheria toxin
catalytic A subunit
Genome-wide activation and
repression-based screens are robust and
give complementary results.
Off-target effects are extremely low due to
mismatch intolerance.
Perturbation of non-coding elements is
achievable.
Konermann et al., 2015 SAM (synergistic
activation mediator) with
protein components
stably expressed
70,290 sgRNAs
23,430 genes
3 sgRNA/gene
Human A375
(melanoma)
Vemurafenib The crystal structure of Cas9 can inform
effective engineering strategies for gene
activation.
Activation-based screening is an alternative
to cDNA overexpression, and hits have a
high validation rate.
CML, chronic myeloid leukemia; CRISPRa, CRISPR activation; CRISPRi, CRISPR interference; PML, promyelocytic leukemia.
for screening, we believe that CRISPR-based gene activation
and repression approaches will prove very useful for functional
genomics when further developed. The generation of gene
knockouts with wild-type Cas9 has distinct caveats including:
(1) the inability to study essential gene function, (2) the
possibility that indels do not cause a frameshift and thus fail
to aﬀect gene function altogether, (3) the lack of phenotype
in situations of redundancy or when cells do not express a
particular gene, and (4) the reliance on host repair mechanisms
to generate indels. It has been proposed that a combination of
activation and repression-based screening is able to overcome
these problems (Gilbert et al., 2014). CRISPR-mediated activation
can successfully induce the expression of endogenous genes
including those which are not normally expressed in the
system of interest, as well as a full complement of protein
isoforms, acting as a more exhaustive alternative to current
cDNA expression screening. Gene repression using CRISPR
can either utilize dCas9 alone targeted to promoters to block
eﬃcient transcription (Qi et al., 2013), or dCas9 fused to
additional repressor complexes to greatly enhance the repressive
eﬀect. This has been demonstrated to be reversible, achieve
greater knockdown eﬃciency than RNAi, and it can also
be used to target non-coding RNAs (Gilbert et al., 2014).
Limitations of these methods are nonetheless imposed by their
complexity, since they require a larger Cas9 fusion protein
and, in the case of activation, ectopic expression of synthetic
transcription factor complexes. Konermann et al. (2015) designed
a “Synergistic Activation Mediator” system consisting of dCas9
linked to VP64 (a fusion of four copies of the transcriptional
activator VP16), in addition to a separate fusion protein of
two distinct classes of activation domains (p65 and HSF1)
linked to the bacteriophage coat protein MS2, which could
be recruited to the target site via engineered loops in a
modiﬁed sgRNA design. All of these components were required
to achieve the most robust gene activation, which highlights
the challenge of simplifying such systems in order to make
them applicable for diverse screening platforms in diﬀerent cell
types.
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FIGURE 2 | General workflow for screening using CRISPR/Cas9 in pooled versus arrayed approaches. In pooled screening, the viral sgRNA library is
delivered to a single vessel of cells at low multiplicity of infection (MOI), before selections for transduced cells and specific phenotypes are carried out. The output of
the screen is derived from deep sequencing of genomic DNA from the selected versus control cell populations, providing a measure of enrichment or depletion of
each sgRNA in response to selection. In arrayed library screening, more library types and delivery methods are available since sgRNAs are delivered to discreet
populations of cells grown in an arrayed format, preventing an individual cell from possessing multiple sgRNAs with different targets. There may be selection steps
and treatments involved, but this can vary depending on the screen. Phenotypes are identified rather than necessarily being selected for, since the sgRNA
responsible for each phenotype is known based on well location in the original annotated library. The final output for this method is a ranked phenotypic measure for
each sgRNA delivered in the screen, and it may be chosen to detect multiple phenotypes in a single screen. In both methods, Cas9 can be stably expressed in the
cells or co-delivered with the library. Key protocol steps that refer to both screening methods are indicated in pale yellow boxes.
Arrayed CRISPR/Cas9 Screening
All pooled studies thus far have technically employed a forward
genetics approach, whereby phenotypes are selected for and
causative genetic modiﬁcations are revealed from downstream
analysis. However, we envisage that the development of
arrayed CRISPR libraries will enable reverse genetic screens
with a much wider utility in terms of phenotypic read-
out (including ﬂuorescence/luminescence and image-based
approaches); these may one day surpass the current use
of siRNA-based approaches to become the default high-
content screening (HCS) method. The technical challenges
associated with the development of arrayed libraries, that
have previously been a barrier for academic labs, are being
overcome by industry and academic investment in CRISPR-
based research tools. In fact, many academic labs and commercial
companies are already engaged in the development of arrayed
libraries.
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Arrayed libraries are generated in multi-well plates, where
each well contains a virus, vector, or reagent preparation
targeting an individual gene or genomic locus. Using this
type of library, it is possible to explore complex phenotypes
(e.g., morphometric, subcellular localization of a ﬂuorescent
reporter) arising from a vast number of distinct cell perturbations
in parallel, by delivering the library to cells grown in an
arrayed format using automated equipment (Figure 2). DNA
sequencing is not required in the initial screening workﬂow since
cells exhibiting a phenotype of interest can simply be cross-
referenced with the annotated library to reveal the delivered
sgRNA.
Overall, the requirements for arrayed library screening are
very diﬀerent from approaches using pooled libraries. Whilst the
experimental conditions will ultimately vary between screens,
there are at least ﬁve important steps to be considered by the
researcher in arrayed CRISPR screening (Figure 2):
(1) Preparation of cells;
(2) Library delivery;
(3) Acquisition of phenotypes;
(4) Analysis of phenotypes;
(5) Validation of hits.
Preparation of Cells
Ideally, arrayed library screening is performed using cells grown
in 96- or 384-well microwell plates. Compared to siRNA-based
screening, arrayed library CRISPR-based screening may need
to be performed on a longer timescale (Table 2). Typically,
siRNA results in a detectable reduction of mRNA levels within
24–72 h, thus making the time from delivery of the siRNA
to detection of a phenotype relatively short. In contrast, the
kinetics of DSB induction and repair have not been fully
characterized in the context of CRISPR, and they are likely
to diﬀer from the kinetics of natural DSB repair due to Cas9
remaining bound at the target following cleavage. Furthermore,
following repair more time may be needed before a phenotype
is observed, since this requires the gene transcript and protein
level to deplete naturally, in contrast to using si/shRNA which
targets transcripts directly. In pooled applications, at least one
week is usually given to allow repair of the DSB followed
by depletion of the transcript and protein, including selection
for transduced cells using an antibiotic resistance marker or
ﬂow cytometry based sorting. Given these considerations, the
initial number of cells seeded into plates in an arrayed screen
may need to be rather low. For some genes, knockout or
perturbation will signiﬁcantly aﬀect cell ﬁtness, resulting in
unequal cell growth across individual wells of a plate. This
poses a challenge with downstream selection protocols and
normalization of cell numbers across samples. It can also aﬀect
experimental data, since some HCS based phenotypes, such
as cell polarity, utilize parameters that are aﬀected by cell
density. In addition, overgrowth of cells can result in artifacts
due to stress. Large-scale screens require automated handling
equipment that cannot routinely re-plate cells in a subset of wells
from one plate to another. For these reasons, when using arrayed
libraries it is recommended to optimize an eﬀective screening
workﬂow that minimizes the time frame between perturbation
and measurement.
A major point of consideration is whether to use a stable
Cas9-expressing cell line or to introduce Cas9 together with
the sgRNAs. Stable Cas9 cell lines are much easier to handle
and reduce inconsistencies that could arise from variable Cas9
expression or activity levels within a cell pool. However, clonally
derived cell lines may exhibit phenotypic artifacts. It has also
been suggested that co-delivery of Cas9 and sgRNA on a single
vector ensures consistent stoichiometry of both components,
which might be preferable to variable sgRNA expression in a
consistent Cas9 expression background (Malina et al., 2013).
Furthermore, many cell types such as primary cells do not lend
themselves to stable line generation. The recent generation of
Cas9 transgenic mice (Platt et al., 2014) not only enables in
vivo CRISPR-based experiments; it also provides the valuable
opportunity to isolate primary mouse cells for ex vivo culture that
stably express Cas9 without the need for further manipulation,
requiring only the delivery of sgRNAs for screening (Shalem
et al., 2015). If such an approach proves eﬀective, it will certainly
be very useful to generate other mouse lines expressing tissue-
speciﬁc or functionalized Cas9 variants in order to perform
CRISPR activation and repression-based screens in primary cells.
These systems can also be made inducible to allow for temporal
control of Cas9-mediated activity or functions, as well as reducing
any potential negative eﬀects of long-term Cas9 expression.
An alternative to using stable Cas9 cells or transient
transfection of Cas9 expression plasmids is the delivery of
recombinant Cas9 protein. Cas9 protein is available from
multiple commercial suppliers (NEB, Toolgene). This approach
was ﬁrst described for delivery of Cas9/sgRNA ribonucleoprotein
complexes by microinjection into C. elegans (Cho et al., 2013)
and was subsequently used to generate gene knockout mice
and zebraﬁsh (Sung et al., 2014). Both, electroporation and
lipofection-based methods for delivery have been described (Kim
et al., 2014; Zuris et al., 2015). In this case, it has been proposed
that the time from delivery to analysis using in vitro transcribed
sgRNA and Cas9 protein transfection can be less than 3 days,
making this comparable to siRNA-based approaches. Nuclease-
mediated indel rates with these methods were as high as 94%
in Jurkat T cells and 87% in induced pluripotent stem cells
(Liang et al., 2015). Generally, these methods achieve high
eﬃciency of indel generation and low oﬀ-target eﬀects. Recently,
ribonucleoprotein complexes of Cas9 and sgRNA were also used
with donor DNA for HDR in various cell types (Lin et al., 2014).
Despite these promising reports, the current cost of recombinant
Cas9 protein is likely to be prohibitive for its use in arrayed library
screening.
Library Delivery
The nature of arrayed library screening means that a
range of library types and delivery methods are available.
Library types can broadly be grouped into those based on
plasmid or viral expression vectors, and those using synthetic
oligonucleotides. Screening with CRISPR could use multiple
possible conﬁgurations, which could include combinations
of a stable cell line expressing Cas9 plus lentiviral-delivered
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sgRNAs, plasmid-based or synthetic guide RNA. Alternatively,
transient expression of Cas9 or transfection of recombinant
Cas9 protein can be used in combination with the guide RNA.
It is also possible to generate screening libraries for any of the
diﬀerent functionalities. In Table 1, we have summarized the
diﬀerent requirements for sgRNA library design depending on
the functionalized Cas9 that is being used.
A key advantage of vector-based systems is that bi-cistronic
expression of a selection marker is possible, allowing for selection
of Cas9- and/or sgRNA-expressing cells. This can be an antibiotic
(e.g., puromycin) resistance marker, or a ﬂuorescent protein.
Both methods of selection work reasonably well and choice of
selection method is mainly guided by the availability of the
respective tools, and whether incompatible reporters are used
for Cas9 expression selection or for phenotypic measurements.
It may be best to avoid selecting cells using antibiotics that
rely on the introduction of DNA double strand breaks such as
zeocin or bleomycin. In arrayed screening coupled with high-
content microscopy, ﬂuorescent selection would likely be done
through segmentation of ﬂuorescent cells in image analysis rather
than through ﬂow sorting, which is better suited for pooled
approaches.
In expression vectors, RNA polymerase III-dependent
transcription of the sgRNA is driven by a U6 or, less commonly,
a H1 promoter. A direct comparison of these two promoter
types has not been done to date. Previous analysis of U6 and
H1 promoter mediated transcription has shown that in certain
cell types such as endothelial cells and in mouse brain, the U6
promoter is more eﬃcient (Makinen et al., 2006). Whilst the
U6 promoter has a requirement for the base “G” to initiate
transcription, this does not necessarily limit potential target sites
since it was shown that always using G as the 5′ nucleotide of
an sgRNA is preferable for its expression, and remains eﬃcient
(at least for knockout-based screens) regardless of whether
this matches the intended target sequence (Mali et al., 2013b;
Koike-Yusa et al., 2014). H1 mediated transcription can result
in variability of small RNA transcripts due to multiple start sites
at the 5′-end (Ma et al., 2014), making U6 promoters the overall
preferred choice for sgRNA expression. An alternative is the use
of very short tRNA promoters to express cleavable tRNA–sgRNA
chimeras (Meﬀerd et al., 2015), but a more detailed analysis of
this strategy remains to be done.
Lentiviral Vectors
At present, the most common method for sgRNA library
expression is through the use of lentiviral vectors. Additionally,
most companies place an emphasis on generating lentiviral
libraries, both pooled and arrayed, presumably due to the
limited processing and library delivery steps required by the
end user. However, handling such libraries requires access to
biosafety level 2 facilities which can be very costly. The main
advantage of using lentiviruses is the ability to infect a broad
range of cell types with high eﬃciency, and without the need
for additional delivery reagents. For arrayed screens, infection
could be carried out at high MOI to ensure that the majority
of cells express one or more copies of the sgRNA expression
cassette.
Lentiviruses integrate into the host genome, maintaining
sgRNA expression over a long period of time, which has
both advantages and disadvantages for screening. On the one
hand, sustained sgRNA expression may increase the likelihood
of on-target modiﬁcations over time, and indeed, this has
previously been seen to be the case and is particularly
noticeable for less eﬃcient sgRNAs (Shalem et al., 2014). On
the other hand, it may increase the likelihood of oﬀ-target
modiﬁcations. Also, integration events occur at random sites,
potentially leading to artifacts such as oncogene activation
when looking at clonal populations of cells. It has not been
conclusively shown whether such long-term expression is an
absolute requirement for CRISPR-based knockout screening,
as transient delivery of sgRNA or crRNA works reasonably
eﬀectively (Kim et al., 2014; Glemzaite et al., 2015). However,
for silencing or activation screens, it remains to be seen
how rapidly dCas9 may dissociate from the target site if
guide RNA expression is not maintained. If this proves to be
an issue, then the long-term sgRNA expression aﬀorded by
lentiviruses will make them the preferred vector choice for such
screens.
AAV Vectors
Increasingly, adeno-associated viral (AAV)-based vectors have
been used for delivery of the sgRNA to cells, and have
been particularly successful for in vivo delivery of Cas9
and sgRNAs to the brain (Swiech et al., 2015). AAV-
based vectors are non-integrating, making it more diﬃcult
to identify sgRNA traces in pooled approaches by next-
generation sequencing, although they can be detected by
episomal sequencing. Since there is no requirement for sgRNA
sequencing during arrayed screens, AAV vectors are well suited
for this application, especially if integration and long-term
sgRNA expression are a particular concern, but eﬃcient delivery
is required.
Plasmid Vectors
The classic approach for delivering sgRNAs in a standard
CRISPR experiment is through transient transfection of a
plasmid vector, and arrayed screening allows this deliverymethod
to be adopted. Plasmids do not suﬀer from the same size
constraints as viral vectors, therefore the convenient delivery
of Cas9 and sgRNA expression cassettes on the same plasmid
is common. Plasmids libraries have the advantage of being
replenishable by propagation in bacteria. Some cell types, such as
HEK293T cells, lend themselves well to plasmid-based screening,
since they can be transfected with eﬃciencies close to 100%
using standard transfection reagents such as calcium phosphate,
polyethylenimine, and lipid-based reagents. However, a number
of other cell types including primary cells are refractory to
these transfection methods; electroporation is typically used to
overcome such problems (Luft and Ketteler, 2015). It can be
diﬃcult to control the expression level of Cas9 and sgRNA
by plasmid transfection, therefore this method may impose
a trade-oﬀ between transfection eﬃciency and possible oﬀ-
target activity and artifacts caused by overexpression of sgRNAs
and Cas9.
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Synthetic Oligonucleotides
An alternative to the use of vector-based systems is the delivery of
synthetic oligonucleotides. In principle, it is possible to generate
RNA only libraries of the sgRNAs. A transient transfection
approach for sgRNAs would be carried out in a similar manner
to siRNA screening, which is currently the most popular method
for genome-wide functional studies. Whilst the length of an
individual sgRNA in nucleotides is much longer than RNA in
classical siRNA libraries (>100 nt compare to 21 nt), they can
still be commercially synthesized with reasonable accuracy, albeit
at a greater cost.
Co-transfection of the target-speciﬁc crRNA plus a common
tracrRNA is feasible and has been successfully used (Kim
et al., 2014; Glemzaite et al., 2015), bringing the possibility
of generating a library of crRNAs to co-introduce with the
tracrRNA. This arrangement is already used alongside transient
Cas9 transfection in the Edit-R system from Dharmacon, with
other companies, including Sigma-Aldrich and ThermoFisher,
currently exploring similar options. Since the tracrRNA can
be commercially obtained in large quantities, using a synthetic
three-component system is generally the most cost-eﬀective
option for screening. The crRNA has a 20 nt sequence speciﬁc
to the genomic DNA target site plus another 20–30 nt sequence
for interaction with the tracrRNA, making it considerably
shorter and cheaper to synthesize than an entire sgRNA. To
date, a single delivery system based on the sgRNA has been
favored for simplicity. Whilst relatively costly for large arrayed
libraries, this may be a very reasonable option for limited
sets of pathway genes, and is aﬀordable compared to current
pricing models for lentiviral sgRNA constructs. Furthermore,
chemical modiﬁcations to the sgRNA can improve genome
editing eﬃciency, in particular when co-delivered with Cas9
mRNA or protein (Hendel et al., 2015). It can be expected that
such modiﬁcations will result in improved library design similar
to advances in siRNA library design by chemical modiﬁcations
that resulted in enhanced on-target and reduced oﬀ-target
activity (Mohr et al., 2014).
Such platforms may allow phenotypic analysis within 3 days
after delivery since they do not depend on integration and/or
expression to have an eﬀect, but the eﬃciency of this technology
needs to be explored. This approach remains attractive compared
to other delivery methods, both in terms of overall costs
and reducing the number of steps necessary to prepare
delivery reagents for screening, and thus we recommend
that oligonucleotide-based CRISPR screening libraries and
technology should be developed further in the future. One
potential disadvantage, however, is the inability to easily select
for cells that have taken up synthetic guide RNA. One possibility
is to label the transfected RNA with ﬂuorescent probes. Several
companies oﬀer kits for labeling siRNA with ﬂuorescent dye to
visualize transfected cells without aﬀecting eﬃcacy. It remains to
be seen whether this is also possible for guide RNAs.
Acquisition of Phenotypes
Pooled libraries require strong phenotypes that can be enriched
by positive or negative selection (Shalem et al., 2015). This has
limited the use for high-content imaging based methods that
observe complex cellular phenotypes as opposed to simple binary
responses. The availability of arrayed siRNA libraries in the
early 2000’s greatly facilitated the use of HCS based methods
in functional genomics (Kiger et al., 2003). A wide range of
cell-based phenotypes can be visualized including morphological
features (Kiger et al., 2003; Yin et al., 2013), organelle dynamics
(Ferraro et al., 2014), protein traﬃcking (Liberali et al., 2014)
and post-translational protein modiﬁcations such as protein
phosphorylation (Papageorgiou et al., 2015). An overview on
HCS and phenotypic analysis is given elsewhere (Liberali et al.,
2015). The analysis of phenotypes in a typical HCS experiment
can be complex and involve multivariate proﬁling of hundreds
of features (Loo et al., 2007; Rameseder et al., 2015). Some HCS
assays such as those based on protein translocation enable the
identiﬁcation of striking phenotypes in a small sub-set of cells
(Freeman et al., 2012), but in most cases a high penetrance
of the phenotype in the majority of cells is required. This
has been achieved using siRNA based methods coupled to
sophisticated image analysis programs so that even heterogeneity
in cell populations can be determined (Snijder et al., 2012). The
penetrance of a phenotype (i.e., the number of cells displaying
a phenotype upon introduction of the perturbation) elicited
by CRISPR/Cas9 has not yet been determined. Eﬃciencies of
knockout using the CRISPR/Cas9 system have been reported in
the range from 10 to 90 % and are dependent on the choice of cell
line. Overall, it is not clear whether sgRNA or crRNA libraries
will enable robust phenotype identiﬁcation without the necessity
of a selection step. Alternatively, it might be necessary to use co-
delivery of reporter genes in order to tag and identify the guide
RNA-containing cells, assuming that the actual modiﬁcation
eﬃciency is very high.
Analysis of Phenotypes
High-content screening assays can involve multi-parametric
analysis, although in reality most published high-content screens
only use a limited number of features for analysis (Singh
et al., 2014). For this purpose, most HCS platforms come with
a commercial high-content analysis package such as InCell
Analyzer (GE Healthcare), Harmony (PerkinElmer Inc), or
Metamorph (Molecular Devices, LLC.). In addition, multiple
software programs for high-content analysis exist that are freely
available to the community, such as CellProﬁler (Carpenter et al.,
2006) and ImageJ/Fiji (Schindelin et al., 2012). Detailed protocols
for high-content analysis are available elsewhere (Misselwitz
et al., 2010; Stoter et al., 2013).
Validation of Hits
Whilst it would be preferable to include validation steps a typical
arrayed screening protocol to minimize bias, current validation
methods are highly resource-intensive which limits the ability
to carry them out on a large scale. For example, detection of
indels requires speciﬁc primer sets that cover each target locus;
these would need to be designed and tested, representing an
enormous cost that could easily dwarf the cost of the screen
itself. Therefore it is recommended to focus on validation of
hits post-screen. The techniques available for doing this can also
be usefully implemented for initial screen development, such as
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for comparing the eﬃciency of diﬀerent guide RNA and Cas9
delivery methods when targeting a small set of test genes.
Common standards for validation of hits and rescue of
phenotypes in CRISPR experiments have yet to be agreed.
However, it is quite important to verify exact genome
modiﬁcations at the sequence level to rule out artifacts. For
instance, the introduction of indels can lead to functional
consequences other than disruption of the gene, such as
expression of alternative frameshift proteins (Ketteler, 2012).
Diﬀerent types of validation experiments will be required
for screens utilizing diﬀerent CRISPR methods. All methods
targeting protein-coding genes beneﬁt from analysis of protein
expression level by western blot if primary antibodies are
available, and RT-qPCR can be used compare transcript levels
where this is not possible or when non-coding RNAs are targeted.
In addition to detection of the underlying genome modiﬁcation
and its eﬀect on transcription and translation, it is important to
validate gene-speciﬁc eﬀects (and thus rule out oﬀ-target eﬀects)
by rescue experiments or reproducing a phenotype usingmultiple
independent guide RNA sequences, as discussed in more detail
below.
Detection of Genome Modification
There are two categories of detection methods. The ﬁrst is to
detect whether a change has occurred in the DNA sequence; these
methods are typically used for initial identiﬁcation of modiﬁed
cell pools and comparing overall modiﬁcation eﬃciencies.
The other is to detect the exact genome modiﬁcation, for
instance by Sanger or next-generation DNA sequencing for
gene knockouts/knockins or methylome analysis for epigenetic
changes, however, this approach requires clonal cell populations.
A quick method for identiﬁcation of indels is based on
enzyme mismatch cleavage assays (Langhans and Palladino,
2009). The surveyor nuclease Cel1 or T7 endonuclease T7E1
are mismatch-speciﬁc DNA endonucleases that will cleave
mismatched heteroduplex DNA and produce two smaller
fragments that can be resolved by gel electrophoresis. A recent
comparison between Cel1 and T7E1 indicates that T7E1 enzymes
preferentially cleave deletions, whereas Cel1 is able to detect
single nucleotide changes (Vouillot et al., 2015). An alternative
method uses native poly-acrylamide gel electrophoresis (PAGE)
to identify indels (Zhu et al., 2014). In this method, PCR
fragments of the target region are denatured and re-annealed
resulting in homo- and hetero-duplexes. Heteroduplexes of DNA
with a mismatch harbor an open angle between the matched and
mismatched DNA strand, which will result in slower migration
during native PAGE. Thus, even in the absence of a mismatch
endonuclease, a diﬀerent migration pattern can be detected that is
indicative of indels. However, these assays often lack quantitative
sensitivity and are relatively low-throughput.
A more scalable and sensitive method to identify indels in cell
populations is to use high resolution melt (HRM) analysis (Price
et al., 2007; Dahlem et al., 2012). In this method, amplicons of
50–300 bp are generated to allow detection of diﬀerences in the
melting curves when indels are present (Thomas et al., 2014).
HRM analysis can also be used to detect oﬀ-target mutations.
This analysis can be done on standard qPCR machines that
are present in most research institutes. One limitation is that
deletions larger than the selected amplicon size will not be
identiﬁed. A variant of this method uses automated capillary
electrophoresis (Yang et al., 2015). In this method, the amplicon
is labeled with ﬂuorescent tags using tri-primer PCR. The
ﬂuorescently labeled amplicons are then detected by fragment
analysis on an ABI3010 sequenator. This method can reliably
identify as little as single nucleotide changes and kits for amplicon
labeling are commercially available. The main disadvantage is
that this method requires equipment for fragment analysis such
as the ABI3010 that is a major added expense for most labs.
More complex systems include reporter cells tomeasure DSBs,
such as the Traﬃc Light Reporter (Kuhar et al., 2014), which
can reliably and simultaneously measure NHEJ and HDR. This
requires the introduction of GFP/mCherry cassettes into cells and
thus is not particularly practical for post-screening validation.
However, this technology may have utility during initial screen
development, as long as the reporter is introduced into the same
type of cell that will be used for the actual screen, since diﬀerent
cell types are expected to have diﬀerent modiﬁcation eﬃciencies.
Detecting an exact genome modiﬁcation in clonal cell
populations can be achieved by next-generation sequencing
or Sanger sequencing. Sanger sequencing is more suitable for
haploid cells, since multiple allelic modiﬁcations would likely give
rise to a mixed sequencing trace, making it diﬃcult to interpret
exact sequence changes. One limitation for Illumina or 454
sequencing is that due to the short read-length, the detection of
large modiﬁcations cannot be accomplished. A sequencing-based
method that produces larger amplicons termed single molecule
real time sequencing (SMRT) can generate read lengths of up to
15 kb and is suitable for detecting large-scale genomic changes
(Hendel et al., 2014).
Rescue of Phenotype
With a lack of standards for validation of CRISPR-generated
phenotypes, problems arise from the analysis and relevance of
clonal populations. A key question is whether one needs to
consider multiple clones for conﬁrmation of phenotypes, and if
so, how many? It seems that generating clones using diﬀerent
guide sequences targeting the same gene provides the best way
to validate a phenotype, but this may not always be possible
due to limitations imposed by the PAM and the potentially
variable functional outcomes of targeting diﬀerent loci within
a gene. Further, a desired feature for validation is to revert a
phenotype by rescue experiments. For knockout or repression
phenotypes, this can be achieved by cDNA expression. For
activation phenotypes (e.g., by CRISPRa), this can be achieved
by si/shRNA-mediated reduction of the gene transcripts. It will
be important to revert expression levels back to physiological
levels, but titrating the exact expression levels can be a challenge
with classical cDNA and si/shRNA techniques. An alternative is
to use BAC-mediated expression to achieve more physiological
levels of gene expression (Poser et al., 2008), or to apply CRISPR-
mediated genome engineering (e.g., gene knock-in), but the latter
might be challenging in cases where indels largely disrupt genes.
Inducible systems would be desirable, but these are not applicable
to irreversible modiﬁcations such as the generation of knockouts.
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In general, this is an issue that requires further experimentation
and discussion before a consensus is met between CRISPR users
within the scientiﬁc community.
Conclusion and Outlook
Overall, the use of CRISPR based methods in high-throughput
functional genomics screening is still in its infancy. The ﬁrst
pooled libraries show encouraging results, but many technical
considerations need to be explored for the development of
arrayed libraries. The generation of large-scale libraries is possible
not only for human and mouse, but virtually any organism. In
the past, siRNA libraries have mostly focused on Drosophila,
C. elegans, human, mouse, and rat genomes, though in principle
has always been possible to design and produce libraries for other
organisms as well. It is uncertain which model organisms will be
targeted with whole genome or focused libraries using CRISPR as
the availability of whole-genome sequence information expands.
Issues such as target site accessibility have not been
experimentally explored. There are indications that sgRNA
targeting is not inﬂuenced by local chromatin structure, whereas
other reports propose that chromatin accessibility contributes
to Cas9 binding (Kuscu et al., 2014; Wu et al., 2014). Some
cases report that increased cleavage eﬃciency correlates with
high GC content adjacent to the PAM (Ren et al., 2014). In
general, the contribution of sequence and chromatin structure
on gene editing needs to be more formally addressed. In addition,
understanding the contribution of PAMproximal and PAMdistal
sequences for Cas9 target binding and cleavage are crucial for
the design of high quality libraries. It was suggested that the
major determinant for on-target activity is a “seed sequence”
proximal to the PAM motif (Kuscu et al., 2014; Wu et al., 2014),
whereas the PAM distal sequence is required for eﬃcient target
recognition and cleavage, but less so for initial binding (Cencic
et al., 2014). This is of particular importance for determining
potential oﬀ-target activities.
Another key point of consideration is that CRISPR library
design to date has focused on gene exon elements. There are
multiple other genomic elements that can be targeted, such
as long non-coding RNAs, UTR regions or the mitochondrial
genome. Further, this may provide a way to dissect the function
of introns, an understudied area of functional genomics (Chorev
and Carmel, 2012). It can be expected that developments in
these areas will ﬂourish in the future. A large variety of sgRNA
libraries can be designed, each for speciﬁc functionalization or
target regions – possibly too many for most screening facilities to
host. Thus, it remains to be seen which ones will be commercially
viable.
Most current screening eﬀorts focus on use of the S. pyogenes
Cas9 protein, but it can be expected that Cas9 isoforms from
other organisms have advantages in terms of delivery and
functionality. The use of other type II Cas proteins can oﬀer
an opportunity to multiplex and/or use other PAM motifs
for increased variety in target sequence recognition. A recent
report has very elegantly demonstrated an expansion of the
PAM motif repertoire for S. pyogenes Cas9 and suggests that
engineering a wide range of Cas9s with altered and improved
PAM speciﬁcities is possible (Kleinstiver et al., 2015). In addition,
Cas9 can be directed to cleave single stranded RNA instead of
DNA (O’Connell et al., 2014), a property that can be exploited for
transcript-based approaches in gene silencing.
Finally, CRISPR screening has become a possibility in 3D
models, tissues and whole organisms (Platt et al., 2014; Chen
et al., 2015). The generation of a Cre-dependent Cas9 knockin
mouse enables the manipulation of genes in speciﬁc tissues,
for instance by viral or non-viral delivery of sgRNA to the
brain or other tissues. Importantly, this technology for the ﬁrst
time enables complex studies of acute modulation of brain-
speciﬁc phenotypes, which will be key to develop a more
thorough understanding of neuronal diseases. Using tissue-
speciﬁc expression systems, it is thus possible to target a
functionalized protein to any location within a whole organism.
This truly is a new age in functional genomics.
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